Brain injection aims to halt devastating dementia
Disease control
Recruiting now
This early-stage study is testing a one-time gene therapy called PBFT02 for adults with specific genetic forms of frontotemporal dementia (FTD). The therapy is delivered via a single injection into the spinal fluid, aiming to deliver a working copy of a missing or faulty gene to …
Phase: PHASE1, PHASE2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC